GEMSP exerts a myelin-protecting role in the rat optic nerve

References

• Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, et al.. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler. 2010;16:406–11.
   PubMed Web of Science ®Google Scholar
• Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, et al.. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol. 2009;66:310–22.
   PubMed Web of Science ®Google Scholar
• Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S, Lepore V, et al.. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One. 2012;7:e48078.
   PubMed Web of Science ®Google Scholar
• Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol. 2005;16:315–20.
   PubMedGoogle Scholar
• Roodhooft JM. Ocular problems in early stages of multiple sclerosis. Bull Soc Belge Ophtalmol. 2009;313:65–8.
   PubMedGoogle Scholar
• Fridkis-Hareli M, Santambrogio L, Stern JN, Fugger L, Brosnan C, Strominger JL. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J Clin Invest. 2002;109:1635–43.
   PubMed Web of Science ®Google Scholar
• Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A. 2000;97:11472–7.
   PubMed Web of Science ®Google Scholar
• Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Aström M, et al.. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163–72.
   PubMed Web of Science ®Google Scholar
• Floris S, Ruuls SR, Wierinckx A, van der Pol SM, Döpp E, van der Meide PH, et al.. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol. 2002;127:69–79.
   PubMed Web of Science ®Google Scholar
• Mangas A, Covenas R, Bodet D, de Leon M, Duleu S, Geffard M. Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model. Int J Biol Sci. 2008;4:150–60.
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley A, et al.. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: Clinical and immunological studies. Ann N Y Acad Sci. 2004;1029:239–49.
   PubMed Web of Science ®Google Scholar
• van der Meide PH, de Labie MC, Ruuls SR, Groenestein RJ, Botman CA, Olsson T, et al.. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in lewis rats. rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol. 1998;84:14–23.
   PubMed Web of Science ®Google Scholar
• Geffard M, Duleu S, Bessede A, Vigier V, Bodet D, Mangas A, et al.. GEMSP: a new therapeutic approach to multiple sclerosis. Cent Nerv Syst Agents Med Chem. 2012;12:173–81.
   PubMedGoogle Scholar
• Mangas A, Covenas R, Geffard M. New drug therapies for multiple sclerosis. Curr Opin Neurol. 2010;23:287–92.
   PubMed Web of Science ®Google Scholar
• Geffard M, de Bisschop L, Duleu S, Hassaine N, Mangas A, Covenas R. Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discov Med. 2010;10:443–51.
   PubMed Web of Science ®Google Scholar
• Mangas A, Covenas R, Bodet D, Dabadie MP, Glaize G, Geffard M. Evaluation of the effects of a new drug on brain leukocyte infiltration in an experimental model of autoimmune encephalomyelitis. Lett Drug Des Discov. 2006;3:138–48.
   Web of Science ®Google Scholar
• Villoslada P, Abel K, Heald N, Goertsches R, Hauser SL, Genain CP. Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. Eur J Immunol. 2001;31:2942–50.
   PubMed Web of Science ®Google Scholar
• Weissert R, Wallstrom E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, et al.. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest. 1998;102:1265–73.
   PubMed Web of Science ®Google Scholar
• Aktas O, Waiczies S, Zipp F. Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol. 2007;184:17–26.
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003;206:165–71.
   PubMed Web of Science ®Google Scholar
• Hobom M, Storch MK, Weissert R, Maier K, Radhakrishnan A, Kramer B, et al.. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 2004;14:148–57.
   PubMed Web of Science ®Google Scholar
• Fairless R, Williams SK, Hoffmann DB, Stojic A, Hochmeister S, Schmitz F, et al.. Preclinical retinal neurodegeneration in a model of multiple sclerosis. J Neurosci. 2012;32:5585–97.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One. 2012;7:e36847.
   PubMedGoogle Scholar
• Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H, Keser N, et al.. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int. 2012;2012:530305.
   PubMedGoogle Scholar
• Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, et al.. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler. 2013;19(4):443–50.
   PubMed Web of Science ®Google Scholar
• Dorr J, Wernecke KD, Bock M, Gaede G, Wuerfel JT, Pfueller CF, et al.. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One. 2011;6:e18132.
   PubMed Web of Science ®Google Scholar
• Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, et al.. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler. 2011;17:1449–63.
   PubMed Web of Science ®Google Scholar
• Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, et al.. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134:e193; author reply e194.
   PubMedGoogle Scholar
• Bock M, Brandt AU, Dorr J, Pfueller CF, Ohlraun S, Zipp F, et al.. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler. 2010;16:893–6.
   PubMed Web of Science ®Google Scholar
• Mangas A, Covenas R, Bodet D, Duleu S, Geffard M. A new drug candidate (GEMSP) for multiple sclerosis. Curr Med Chem. 2009;16:3203–14.
   PubMed Web of Science ®Google Scholar
• Mangas A, Covenas R, Bodet D, Geffard M. Antisera and immunocytochemical techniques. In: Mangas A; Covenas R, Geffard M (eds.) Brain molecules: from vitamins to molecules for axonal guidance. Trivandrum: Transworld Research Network; 2008, 1–25.
   Google Scholar
• Covenas R, Mangas A, Jaulain C, Geffard M. Multiple sclerosis. In: Sugaya K and Samsam M, (eds.) Molecular and clinical neuroscience. Plymouth: McNeil, in press.
   Google Scholar
• Althaus HH. Remyelination in multiple sclerosis: A new role for neurotrophins? Prog Brain Res. 2004;146:415–32.
   PubMed Web of Science ®Google Scholar
• Reiter RJ. Potential biological consequences of excessive light exposure: Melatonin suppression, DNA damage, cancer and neurodegenerative diseases. Neuro Endocrinol Lett. 2002;23(Suppl.2):9–13.
   PubMedGoogle Scholar
• Teufel M, Saudek V, Ledig JP, Bernhardt A, Boularand S, Carreau A, et al.. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem. 2003;278:6521–31.
   PubMed Web of Science ®Google Scholar
• Gillson G, Wright JV, DeLack E, Ballasiotes G. Transdermal histamine in multiple sclerosis: part one – clinical experience. Altern Med Rev. 1999;4:424–8.
   PubMedGoogle Scholar
• Wuerfel J, Paul F, Zipp F. Cerebral blood perfusion changes in multiple sclerosis. J Neurol Sci. 2007;259:16–20.
   PubMed Web of Science ®Google Scholar
• van Meeteren ME, Teunissen CE, Dijkstra CD, van Tol EA. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr. 2005;59:1347–61.
   PubMed Web of Science ®Google Scholar
• Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006;141:312–22.
   PubMed Web of Science ®Google Scholar
• Helgestad J, Storm-Mathisen I, Lie SO. Vitamin C and thiol reagents promote the in vitro growth of murine granulocyte/macrophage progenitor cells by neutralizing endogenous inhibitor(s). Blut. 1986;52:1–8.
   PubMedGoogle Scholar
• Iwata-Ichikawa E, Kondo Y, Miyazaki I, Asanuma M, Ogawa N. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J Neurochem. 1999;72:2334–44.
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J Neurol. 2004;251:261–8.
   PubMed Web of Science ®Google Scholar
• Herges K, Millward JM, Hentschel N, Infante-Duarte C, Aktas O, Zipp F. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One. 2011;6:e25456.
   PubMed Web of Science ®Google Scholar
• Di Biase A, Salvati S. Exogenous lipids in myelination and myelination. Kaohsiung J Med Sci. 1997;13:19–29.
   PubMedGoogle Scholar
• Medina JM, Tabernero A. Astrocyte-synthesized oleic acid behaves as a neurotrophic factor for neurons. J Physiol Paris. 2002;96:265–71.
   PubMed Web of Science ®Google Scholar